Oligodendrogliomas.
Although oligodendrogliomas cannot be considered benign tumors, many are slow-growing indolent tumors for which prolonged life expectancy is the rule. Others behave in a more aggressive, malignant fashion, as would be predicted by their histologic characteristics. The treatment for oligodendrogliomas is evolving, with conservative management still reserved for nonanaplastic tumors, and increasingly aggressive systemic therapies being developed for more aggressive or recurrent tumors.
Peterson
K
K
Department of Neurology, University of Minnesota, Minneapolis, USA.
Cairncross
J G
JG
D000328:Adult; D001921:Brain / Q000473:pathology; D001932:Brain Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000628:therapy; D009837:Oligodendroglioma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D015996:Survival Rate